Laboratorio Reig Jofre's Financial Metrics Adjusted Amidst Growth and Leverage Concerns

Laboratorio Reig Jofre SA, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment that reflects a shift in its underlying financial metrics. The company's quality score has been revised, indicating a notable change in its financial standing.
Over the past five years, Laboratorio Reig Jofre has reported a sales growth of 13.10% and an EBIT growth of 10.93%. However, the average Return on Capital Employed (ROCE) stands at 4.49%, suggesting challenges in generating returns relative to capital invested. The company's debt metrics reveal a Debt to EBITDA ratio of 1.12 and a Net Debt to Equity ratio of 0.22, which may raise concerns regarding its leverage.

Additionally, the stock's performance has lagged behind the broader market, with a return of 10.45% over the past year compared to the Spain IBEX 35's return of 37.89%. The dividend payout ratio is noted at 30.60%, while the tax ratio is at 12.31%. These metrics collectively contribute to the recent adjustment in evaluation for Laboratorio Reig Jofre SA.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.